ReviewTranslational lung cancer research2021
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer.
Review in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 29 citations in OpenAlex.
- Dosing, duration, and timing controversies in determining immune checkpoint inhibitor dosing regimens.NPJ precision oncology · 2026Article
- Article
- Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy.Frontiers in immunology · 2026Article
- Circulating Tumor Cell PD-L1 and Peripheral Blood CD8Cancer management and research · 2026Article
- Global research trends of immunosenescence and immunotherapy: A bibliometric study.Human vaccines & immunotherapeutics · 2025Review
- Quality-of-life scale machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer.Frontiers in immunology · 2025Article
- The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches.Frontiers in immunology · 2025Review
- Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects.Heliyon · 2024Review
- Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Thoracic cancer · 2024Article
- Plasma extracellular vesicle long RNA profiling identifies a predictive signature for immunochemotherapy efficacy in lung squamous cell carcinoma.Frontiers in immunology · 2024Article
- An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.Thoracic cancer · 2024Article
- Pretreatment eosinophil counts as a predictive biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.Thoracic cancer · 2023Article
- Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer.Cancer science · 2023Article
- ING5 overexpression upregulates miR-34c-5p/Snail1 to inhibit EMT and invasion of lung cancer cells.Acta biochimica et biophysica Sinica · 2023Article
- Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer.Scientific reports · 2023Article
- Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.Current oncology (Toronto, Ont.) · 2023Review
- Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer.Frontiers in oncology · 2023Article
- Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.Therapeutic advances in medical oncology · 2023Article
- The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment.Frontiers in oncology · 2023Review
- TFG-β Nuclear Staining as a Potential Relapse Risk Factor in Early-Stage Non-Small-Cell Lung Cancer.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICI) have been validated as an effective new treatment strategy in several tumoral types including lung cancer. This remarkable shift in the therapeutic paradigm is in large part due to the duration of responses and long-term survival seen with ICI. However, despite this, the majority of cancer patients do not experience benefit from ICI. Even among patients who initially respond to ICI, disease progression may ultimately occur. Moreover, in some patients, these drugs may be associated with new patterns of progression such as pseudo-progression and hyper-progressive disease, and different toxicity profiles with immune-related adverse events. Therefore, the identification of predictive biomarkers may help to select those patients most likely to obtain a true benefit from these drugs, and avoid exposure to potential toxicity in patients who will not obtain clinical benefit, while also reducing the economic impact. In this review, we summarize current and promising potential predictive biomarkers of ICI in patients with non-small cell lung cancer (NSCLC), as well as pitfalls encountered with their use and areas of focus to optimize their routine clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.